President Donald Trump’s new executive order on psychedelics is being sold as a compassionate breakthrough for Americans suffering from serious mental illness.
But for families living with schizophrenia, psychosis, and severe bipolar disorder, it looks like a dangerous gamble built on the same failed foundation that has already abandoned our sickest loved ones.
On April 18, 2026, Trumpsigned an orderdirecting federal agencies to accelerate medical treatments for serious mental illness, including psychedelic-based therapies, and to reduce regulatory barriers that slow research and access.
The White Housesaidthis will fast-track “innovative methods” for treating depression, PTSD, addiction, and suicide risk.
Media coverage fromTime Magazine,NPR, and others has largely echoed that enthusiasm.
There is evenspecial interestin powerful drugs like ibogaine.
On the surface, it sounds bold and compassionate. But the order talks broadly about “serious mental illness” while skipping a crucial reality: people with psychosis-related disorders are not the same as patients with depression or PTSD, and the science around psychedelics in this group is thin at best and alarming at worst.
Modern psychedelic trials have largely excluded people with schizophrenia, schizoaffective disorder, and bipolar I with psychosis. Researchers have done that for a reason: fear that psychedelics could worsen psychosis or trigger mania in vulnerable people.
A 2024 study inJAMA Psychiatryfound that psychedelic use was linked to more psychotic and manic symptoms in adolescents with higher genetic risk for schizophrenia or bipolar I, even when they did not yet have a diagnosis.
A summary inNeurology Advisordescribed a “complex” and concerning relationship between psychedelic use, psychosis, and mania.
Source: VidNews » Feed
